

A multicentre, multinational, double blind, randomised, parallel group, placebo-controlled study of ethyl-eicosapentaenoate (EPA) in patients with Huntington's disease (HD)

Submission date 03/02/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 03/02/2003	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 09/02/2011	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Harald Murck

Contact details

Laxdale Ltd
Kings Park House
Laurelhill Business Park
Polmaise Road
Stirling
United Kingdom
FK7 9JQ
+44 (0)1786 476001
hmurck@laxdale.co.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

LA01.01.0005

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Huntington's disease

Interventions

Two groups randomly allocated to placebo or 2 g/day ethyl EPA on a double blind basis.

Patients who completed the 12 month randomisation phase of the trial were invited to take part in a further 12 month open label phase receiving 2 g/day Ethyl EPA.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/2003

Completion date

01/01/2004

Eligibility

Key inclusion criteria

1. Written informed consent
2. Availability of a responsible family member or carer to look after the patient during the trial and ensure complete compliance
3. Diagnosis of HD in stage I

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2003

Date of final enrolment

01/01/2004

Locations

Countries of recruitment

Scotland

United Kingdom

Study participating centre
Laxdale Ltd
Stirling
United Kingdom
FK7 9JQ

Sponsor information

Organisation
Laxdale Ltd (UK)

Sponsor details
Kings Park House
Laurelhill Business Park
Polmaise Road
Stirling
United Kingdom
FK7 9JQ
+44 (0)1786 476001
admin@Laxdale.co.uk

Sponsor type
Industry

Website
<http://www.laxdale.co.uk>

ROR
<https://ror.org/03gc62f43>

Funder(s)

Funder type
Industry

Funder Name
Laxdale Ltd (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	26/07/2005		Yes	No